Alzamend Neuro Inc Stock Price, News & Analysis

Alzamend Neuro, Inc. (Nasdaq: ALZN) received a "Study May Proceed" letter from the FDA to initiate a Phase I/IIA clinical trial for ALZN002, an immunotherapy targeting mild to moderate dementia associated with Alzheimer’s. The trial aims to assess the safety and efficacy of the patient-specific treatment using autologous dendritic cells. Alzamend plans to dose the first patient in Q1 2023. Encouraging pre-clinical results show significant amyloid plaque reductions and no adverse side effects, supporting the IND application.

Alzamend Neuro (NASDAQ: ALZN) has commenced dosing in its Phase IIA study of AL001 for Alzheimer’s-related dementia.

The trial, initiated in May 2022, aims to assess the safety and tolerability of AL001 under multiple-dose conditions.

In response to FDA guidance, Alzamend is expanding the trial to include healthy adults, which may accelerate further testing for bipolar disorder, major depressive disorder, and post-traumatic stress disorder.

AL001 presents a novel lithium delivery option, potentially offering therapeutic benefits with reduced toxicity compared to traditional lithium carbonate.

Alzamend Neuro, Inc. (Nasdaq: ALZN) has submitted an investigational new drug (IND) application to the FDA for ALZN002, an active immunotherapy targeting mild to moderate Alzheimer’s dementia. ALZN002 utilizes patients' dendritic cells to combat amyloid-beta proteins, aiming to offer a durable and safer treatment compared to passive immunization. The upcoming Phase I/IIA trial will assess safety and efficacy in 20-30 subjects. Preclinical studies demonstrated significant amyloid plaque reductions without adverse effects, supporting the IND submission and potential for advancing Alzheimer’s therapies.

Alzamend Neuro, Inc. (Nasdaq: ALZN) announced it has regained compliance with Nasdaq's Minimum Bid Price Requirement. The company received a compliance notice on September 21, 2022, confirming its stock maintained a closing bid price of at least $1.00 for ten consecutive business days from September 7 to September 20, 2022. Earlier, on June 22, 2022, Alzamend had been notified of non-compliance due to the stock price falling below $1.00 for 30 consecutive days. The company focuses on developing treatments for Alzheimer's, bipolar disorder, MDD, and PTSD.

Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that the FDA provided a framework for the clinical development of AL001, a lithium-delivery system for treating bipolar disorder, major depressive disorder, and PTSD. The ongoing Phase IIA trial evaluates AL001's safety and tolerability in Alzheimer's patients, with topline data expected in December 2022. Full results from a Phase I study indicated that AL001 is bioequivalent to lithium carbonate. Alzamend plans to submit IND applications for the additional indications upon completing the current trial.

Alzamend Neuro will present at the 12th Annual LD Micro Invitational from June 7-9, 2022, in Westlake Village, California. CEO Stephan Jackman will speak on June 8 at 12:00 p.m. PT, showcasing the company's accomplishments, including the completion of a Phase I study for AL001 and the initiation of a Phase IIA study. Alzamend is also preparing to submit an IND for AL002. The event will be accessible both live and virtually, with mandatory registration. More details can be found on their website.

Alzamend Neuro, Inc. (Nasdaq: ALZN) has submitted a Pre-IND meeting request to the FDA for its novel lithium-delivery system, AL001, targeting bipolar disorder, major depressive disorder, and PTSD. AL001 aims to deliver lithium's benefits while reducing toxicities. A Phase IIA trial for dementia related to Alzheimer's is ongoing, with topline data expected in December 2022. The trial evaluates safety and tolerability in patients with Alzheimer's. The company anticipates that AL001 may represent a significant improvement over existing lithium treatments, addressing a large patient population.

Alzamend Neuro (Nasdaq: ALZN) has initiated a 12-month Phase IIA multiple ascending dose study for AL001, aimed at patients with mild to moderate Alzheimer’s disease. The study's primary goal is to assess the safety, tolerability, and maximum tolerated dose of AL001, a novel lithium-delivery system designed to mitigate lithium's toxicities. The Phase I study confirmed AL001's bioequivalence to marketed lithium carbonate at a lower dosage. Topline data is expected by December 2022, marking a significant milestone for Alzamend in developing treatments for neurodegenerative diseases.

Alzamend Neuro (ALZN) has announced positive results from its Phase 1 trial for AL001, a new lithium-delivery system aimed at treating Alzheimer's disease. The data confirm that AL001 is bioequivalent to marketed lithium carbonate, establishing safety and tolerability. Based on these results, the company plans to initiate a Phase 2A multiple ascending dose study in May 2022. Additionally, Digital Power Lending, a subsidiary of BitNile Holdings (NILE), has invested $4 million in Alzamend, enabling the company to progress without seeking new capital.